IGF1R has been suggested as a driver of tumor growth in sarcomas [64], and ganitumab, an IGF1R antibody, is currently being studied in trials for metastatic EWS and advanced sarcomas [65, 66]. This evidence concerns the gene IGF1R and sarcoma.